Yu Yanagisawa received his PhD in Chemical and Biomolecular Engineering, Graduate School of Engineering, The University of Tokyo. During his studies, he conducted research on functional polymer materials in Takuzo Aida’s laboratory. He joined CellFiber in February 2018, became a director in May of the same year, and assumed the position of representative director in June 2019. Immediately after joining the company, he has been serving as a principal investigator in projects sponsored by AMED, NEDO, etc., and has been leading the business of CellFiber.

Aki Adachi received her master’s degree from Graduate School of Arts and Sciences, the University of Tokyo (Shoji Takeuchi Laboratory, Institute of Industrial Science). After working for a private company for several years, she was appointed as the research promoter of the JST ERATO Takeuchi Bio Integration Project. In April 2015, together with Takeuchi, Okitsu, and Onoe, she established CellFiber Co., Ltd. based on the cell fiber technology that was the result of the ERATO project, and became the representative director. Currently, as a board member, she is working to expand the potential and application of Cellfiber technology through lectures and technical presentations in the industry.

Hiroaki Onoe received his PhD in Information Science and Engineering from the University of Tokyo, and had been an assistant professor in Shoji Takeuchi’s lab since April 2009, where he developed cell fiber technology as an assistant researcher and group leader of the ERATO Takeuchi Project. He started his career as an independent PI in the Faculty of Science and Technology at Keio University in April 2014, and has also served as a Board Director of CellFiber since April 2016. In April 2017 he was awarded the Young Scientist Prize of the Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology for his research on in vitro tissue formation including cell fibers.

Kuni Suzuki has been dedicating his last 20 years in the space of cell & gene therapies/regenerative medicine as the management of MEDINET Co., Ltd as CEO, CBO and so on, after his business career starting at ESSO SEKIYU K.K., an affiliate of Exxon Corp, and working at Nikko Securities Co., Ltd. in the area of investment banking, commercial banking and custodian banking over 20 years.

With joining to MEDINET in 2006, he also play an important functions at FIRM (Forum for Innovative Regenerative Medicine), the industrial advocacy for CGT/RM in Japan by working together with ARM, ISCT, CCRM, C&G Catapult and others.

Professor ,The University of Tokyo
Website： http://www.hybrid.iis.u-tokyo.ac.jp/

Specially-appointed professor, The University of Tokyo

Kazuchika Furuishi received his PhD in Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto Univercity.

 He has been in the industry for decades and went through Sales Manager at Global Market of Hitachi Chemical Co., Ltd., Deputy General Manager at Regenerative Medicine Business Sector of Hitachi Chemical Co., Ltd., CEO of Minaris Regenerative Medicine, LLC, and Corporate Officier and General Manager, Regenerative Medicine Business Sector of Showa Denko Materials Co., Ltd.

In Dec 2022, he joined CellFiber. And from July 2023, he became Board Director, Chief Strategic Officer.

Taira Kobayashi is working for JAFCO in the Academia-Industry Collaboration and Life Sciences Investment Group, and has invested and supported R&D startups in various sectors ranging from Deep Tech to drug discovery.

He also serves as a JST-START project promoter, commercializing university-launched ventures, and gives lectures at universities and other institutions based on his career and experience.
Taira previously held a Medical Science Liaison - Central Nervous System and was involved in in-house business planning, including digital health business development and METI projects at TAKEDA Pharmaceutical Co. Ltd. From 2013 to 2017, he served as a researcher at TOYOTA Central R&D Labs, where he was involved in R&D across all engineering fields and promoted business development in neuroscience and artificial cells at the Strategic Research Division. Before TOYOTA, he served as an academic researcher at the Institute of Medical Science - The University of Tokyo(IMSUT) and promoted basic medical research in bacterial infection and innate immunity of human cells.